Comparison of Two Tranexamic Acid Dose Regimens in Patients Undergoing lve Surgery

Objective: Tranexamic acid (TA), a synthetic antifibrinolytic drug, has been shown to reduce postoperative bleeding and the need for allogeneic blood transfusion in cardiac surgery. However, the optimal dose regimen of TA is still under debate. The aim of this study was to evaluate whether a lower-dose TA regimen produced equivalent efficacy to its higher-dose counterpart in reducing postoperative bleeding and transfusion needs. Design: A prospective, randomized, double-blind trial. Setting: National Center for Cardiovascular Diseases & University Hospital, Beijing, People’s Republic of China. Participants: One hundred seventy-five patients undergoing cardiac valve surgery were enrolled in the study. Interventions: All patients were divided randomly into 2 groups. The lower-dose TA group received a loading dose of 10 mg/kg, maintenance dose of 2 mg/kg/h, and a cardiopulmonary bypass pump prime dose of 40 mg; the higherdose TA group received a loading dose of 30 mg/kg,

[1]  S. Grassin-Delyle,et al.  Comparison of Two Doses of Tranexamic Acid in Adults Undergoing Cardiac Surgery with Cardiopulmonary Bypass , 2014, Anesthesiology.

[2]  P. Devillier,et al.  Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. , 2013, British journal of anaesthesia.

[3]  A. Koster,et al.  Moderate Dosage of Tranexamic Acid During Cardiac Surgery With Cardiopulmonary Bypass and Convulsive Seizures: Incidence and Clinical Outcome , 2013 .

[4]  B. Orser,et al.  Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. , 2012, The Journal of clinical investigation.

[5]  J. Pawliszyn,et al.  Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass * , 2012, Anaesthesia.

[6]  D. Cheng,et al.  Tranexamic acid for routine use in off-pump coronary artery bypass surgery: evidence base "fait accompli" or more research needed? , 2012, Anesthesia and analgesia.

[7]  J. Freedman,et al.  Drug, Devices, Technologies, and Techniques for Blood Management in Minimally Invasive and Conventional Cardiothoracic Surgery a Consensus Statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011 , 2012, Innovations.

[8]  Cornelius Lehane,et al.  High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  Howard K. Song,et al.  2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. , 2011, The Annals of thoracic surgery.

[10]  R. Lange,et al.  Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. , 2011, Journal of cardiothoracic and vascular anesthesia.

[11]  A. Koster,et al.  Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era , 2011, Current opinion in anaesthesiology.

[12]  L. Sharples,et al.  Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients. , 2010, The Annals of thoracic surgery.

[13]  D. Royston.  Tranexamic acid in cardiac surgery: is there a cause for concern? , 2010, Critical Care.

[14]  K. Wernecke,et al.  Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis , 2010, Critical care.

[15]  M. Fox.  Tranexamic acid: how much is enough? , 2010, Anesthesia and analgesia.

[16]  S. Marasco,et al.  Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. , 2010, The heart surgery forum.

[17]  D. Ngaage,et al.  Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  J. Murkin,et al.  High-Dose Tranexamic Acid Is Associated with Nonischemic Clinical Seizures in Cardiac Surgical Patients , 2010, Anesthesia and analgesia.

[19]  R. Lange,et al.  The Risks of Aprotinin and Tranexamic Acid in Cardiac Surgery: A One-Year Follow-Up of 1188 Consecutive Patients , 2008, Anesthesia and analgesia.

[20]  B. Reeves,et al.  Increased mortality, morbidity, and cost associated with red blood cell transfusion after cardiac surgery , 2008, Current opinion in cardiology.

[21]  R. Martineau,et al.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. , 2008, The New England journal of medicine.

[22]  G. Nuttall,et al.  A preliminary study of a new tranexamic acid dosing schedule for cardiac surgery. , 2008, Journal of cardiothoracic and vascular anesthesia.

[23]  W. White,et al.  The effect of aprotinin on outcome after coronary-artery bypass grafting. , 2008, The New England journal of medicine.

[24]  Chris A Rogers,et al.  Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery , 2007, Circulation.

[25]  Jeremiah R. Brown,et al.  Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery , 2007, Circulation.

[26]  I. C. Tudor,et al.  The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.

[27]  J. Butterworth,et al.  Pharmacokinetics of Tranexamic Acid during Cardiopulmonary Bypass , 2002, Anesthesiology.

[28]  W. Sieghart,et al.  Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. , 2002, The Journal of pharmacology and experimental therapeutics.

[29]  D. V. Van Riper,et al.  The Dose‐Response Relationship of Tranexamic Acid , 1995, Anesthesiology.

[30]  J. Horrow,et al.  Effect of tranexamic acid on platelet ADP during extracorporeal circulation , 1991, American journal of hematology.

[31]  S. Colleen,et al.  ROLE OF UROKINASE AND TISSUE ACTIVATOR IN SUSTAINING BLEEDING AND THE MANAGEMENT THEREOF WITH EACA AND AMCA , 1968, Annals of the New York Academy of Sciences.

[32]  G. Gravlee.  High-Dose Tranexamic Acid Is an Independent Predictor of Early Seizure After Cardiopulmonary Bypass , 2012 .

[33]  A. Menkis,et al.  Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors , 2011, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[34]  B. Orser,et al.  “Seizing” the opportunity to understand antifibrinolytic drugs , 2011, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[35]  Howard K. Song,et al.  Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines , 2011 .

[36]  G. Gravlee.  Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death , 2009 .

[37]  A. Laupacis,et al.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2001, The Cochrane database of systematic reviews.